215 related articles for article (PubMed ID: 26926942)
1. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.
Vallabhaneni S; Longley N; Smith M; Smith R; Osler M; Kelly N; Cross A; Boulle A; Meintjes G; Govender NP
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e37-e42. PubMed ID: 26926942
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
[TBL] [Abstract][Full Text] [Related]
5. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
6. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
8. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
[TBL] [Abstract][Full Text] [Related]
10. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
[TBL] [Abstract][Full Text] [Related]
11. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
Jarvis JN; Harrison TS; Lawn SD; Meintjes G; Wood R; Cleary S
PLoS One; 2013; 8(7):e69288. PubMed ID: 23894442
[TBL] [Abstract][Full Text] [Related]
13. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care.
Rajasingham R; Meya DB; Boulware DR
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):e85-91. PubMed ID: 22410867
[TBL] [Abstract][Full Text] [Related]
14. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.
Enock K; Julius K; Griffith BC; Abila DB; Rutakingirwa MK; Kasibante J; Kandole KT; Kwizera R; Semeere A; Meya DB
BMC Health Serv Res; 2022 Mar; 22(1):301. PubMed ID: 35246128
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior cryptococcal antigen screening on in-hospital mortality in cryptococcal meningitis or fungaemia among HIV-seropositive individuals in South Africa: a cross-sectional observational study.
Paccoud O; Shuping L; Mashau R; Greene G; Quan V; Meiring S; Govender NP;
Clin Microbiol Infect; 2023 Aug; 29(8):1063-1069. PubMed ID: 37086780
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
[TBL] [Abstract][Full Text] [Related]
20. Preventing deaths from cryptococcal meningitis: from bench to bedside.
Roy M; Chiller T
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):715-7. PubMed ID: 21905781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
